Based on recent comprehensive analyses of the genomic landscape of bladder cancer patients, several mutated genes have been identified as possible therapeutic targets, including epithelial growth factor receptor (EGFR) gene [4]. The gene discussed is EGFR; the disease is urinary bladder carcinoma.